Skip to main content
OpenTrials
Completed

NCT Number: NCT00441116

A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia

The aim of this Phase III study is to compare the efficacy, safety and tolerability of dutasteride (0.5mg) with placebo for 6 months, in Korean male subjects with androgenetic alopecia in the vertex region, types IIIv, IV and V according to the modified Norwood-Hamilton Classification.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Alopecia Hair Diseases Hypotrichosis Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–49 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Rationale - The vertex area of the scalp will be evaluated during this study, therefore the inclusion criterion of Norwood Hamilton areas IIIv, IV or V ensures that subjects with vertex hair loss will be recruited in line with the primary efficacy endpoint of change in hair growth in the vertex.

A subject will be eligible for inclusion in this study only if all of the following criteria apply:

  • Male out-patients aged 18-49 years, inclusive
  • Diagnosis of Male Pattern Hair Loss classified as type IIIv, IV, or V utilising the modified Norwood-Hamilton classification (Figure 1) (N.B. types IVa and Va are excluded)
  • Able to comprehend instructions and record required information
  • Will provide signed and dated written informed consent to participate in this investigation

Exclusion criteria

  • A subject will not be eligible for inclusion in this study if any of the following criteria apply:
  • Evidence of hypogonadism defined as serum testosterone < 250ng/dl and/or LH >20mIU/ml Note: If the initial serum testosterone result is < 250ng/dl and the LH value is normal, the test may be repeated once. Attempts should be made, where possible, to collect all samples in the morning hours. If the repeat testosterone result is < 250ng/dl, the subject is not eligible for participation.
  • Greater than two times the upper limit of normal for ALT or AST, or a bilirubin greater than 2.0mg/dl (exception - subjects diagnosed with Gilbert's syndrome will be eligible to participate in the study)
  • Serum creatinine >1.8mg/dl
  • Global scalp hair thinning, including occipital areas
  • Scarring of the scalp or any other condition or disease of the scalp or hair, including diseases of the hair shaft (e.g., uncontrolled seborrheic dermatitis, tinea infections, other causes of alopecia, prior hair transplants or scalp reductions, psoriatic dermatitis) and inability to discontinue use of hair weaving.
  • Subjects who use hair colourants/hair dyes, or have the remaining traces of colourants in their hair. Subjects must maintain their natural hair colour throughout the study.
  • Hair length in non-balding areas ≤2cm (3/4 inch) around the vertex region of the head. Subjects must maintain the same hairstyle throughout the study.
  • History of malignancy within the past five years, except basal cell or squamous cell carcinoma of the skin
  • Serum PSA level > 2.0 ng/ml at screening visit.
  • Family history(Father, brothers) of prostate cancer.
  • Active unstable thyroid disease, including subjects on therapy for either hyperthyroidism or hypothyroidism unless their dose of thyroid medication has been stable for 3 months and serum TSH is normal
  • Hypersensitivity to any 5 AR inhibitor or drugs chemically related to the study medication
  • Use of finasteride or other 5 AR inhibitors within the 12 months prior to screening.
  • Previous use of dutasteride.
  • Use of phytotherapy (e.g. saw palmetto) within 8 weeks prior to screening.
  • Previous use of cytotoxic agents
  • Use of glucocorticoids (inhaled glucocorticoids are allowed; topical steroids are allowed provided that they are not used on the scalp) within the 3 months prior to screening
  • Use of the following during the 6 months prior to screening:
  • Minoxidil (oral or topical)
  • Drugs with anti-androgenic properties (e.g., cyproterone acetate, spironolactone, ketoconazole, flutamide, bicalutamide). Cimetidine cannot be used during the study but is not an excluded drug when used during the previous 6 months.
  • Topical estrogen, progesterone
  • Tamoxifen
  • Drugs potentially causing hypertrichosis (e.g., cyclosporine, diazoxide, phenytoin psoralens)
  • Anabolic steroids
  • Lithium and phenothiazines
  • Concurrent or regular use during the 4 weeks prior to screening of topical agents to the scalp (e.g., anti-inflammatories) 18. Participation in any investigational or marketed drug trial within 30 days preceding the screening phase of this study. Participation in any other drug trial during the course of this study including the follow-up period.
  • History or current evidence of drug or alcohol abuse within the 12 months prior screening 20. History of any illness (including psychiatric) which may impair the ability to provide informed consent or comply with study requirements 21. History of any unstable illness or condition that, in the opinion of the investigator, might confound the results or put the subject at risk.
  • Subjects who are known to be HIV positive (status which includes subjects with AIDS) 23. Subjects who will not refrain from donating blood until completing the study follow-up period.

Treatment and study plan

Dutasteride 0.5mg oral tablets

Drug

Dutasteride

Primary outcomes

  1. Change From Baseline Hair Growth Assessed by Macrophotographic Technique (Hair Count) in the Vertex at 6 Months.

    Time frame: Baseline and 6 months

    The Macrophotographic hair count method marks a 1-inch diameter circular area at the anterior leading edge of the vertex thinning area and then photographed. The photographs are enlarged and converted into dot maps and the dot maps are converted into total hair counts by means of personal computer-based scanners and imaging software.

Secondary outcomes

  1. Change From Baseline Hair Growth Assessed by Macrophotographic Technique (Hair Count) in the Vertex at 3 Months.

    Time frame: Baseline and Month 3

    The Macrophotographic hair count method marks a 1-inch diameter circular area at the anterior leading edge of the vertex thinning area and then photographed. The photographs are enlarged and converted into dot maps and the dot maps are converted into total hair counts by means of personal computer-based scanners and imaging software.

  2. Subjects Global Assessment of Hair Regrowth Question: Since the Start of Treatment I Have Lost?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index without Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions without photographs concerning their perception of Change in Hair Growth.

  3. Subjects Global Assessment of Hair Regrowth Question: Since the Start of Treatment my Usual Hair Loss Has Slowed Down?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index without Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions without photographs concerning their perception of Change in Hair Growth.

  4. Subjects Global Assessment of Hair Regrowth Question: Since Start of Treatment the Overall Appearance (Thickness, Hair Quality, Amount) of the Hair on my Head is?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index without Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions without photographs concerning their perception of Change in Hair Growth.

  5. Subjects Global Assessment of Hair Regrowth Question: Since the Start of Treatment I Have Kept What Hair I Had?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index without Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions without photographs concerning their perception of Change in Hair Growth.

  6. Subjects Global Assessment of Hair Regrowth Question: Since the Start of Treatment, When I Look at my Thinning Area, I Can See?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index with Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions comparing photographs of their hair before treatment and concerning the last week and evaluated the change in Hair Growth.

  7. Subjects Global Assessment of Hair Regrowth Question: Since the Start of Treatment my Hair Now Covers?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index with Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions comparing photographs of their hair before treatment and concerning the last week and evaluated the change in Hair Growth.

  8. Subjects Global Assessment of Hair Regrowth Question: Since the Start of Treatment the Amount of Hair on my Thinning Area Has?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index with Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions comparing photographs of their hair before treatment and concerning the last week and evaluated the change in Hair Growth.

  9. Subjects Global Assessment of Hair Regrowth Question: Since the Start of Treatment the Appearance (Thickness, Hair Quality, Amount) of the Thinning Area on my Head is?

    Time frame: Month 3 and Month 6

    GlaxoSmithKline - Hair Growth Index with Photographs subject assessment of change in hair loss and overall appearance at 3 and 6 months. Subjects answered 4 questions comparing photographs of their hair before treatment and concerning the last week and evaluated the change in Hair Growth.

  10. Investigator's Photographic Assessment of Improvement Distribution From Baseline

    Time frame: Month 3 and Month 6

    Improvement Distribution is based on the number of hairs per centimeters squared by macrophotographic conversion hair count. Score Range -3=greatly decreased to +3=greatly increased. 0=No change.

  11. Investigator's Photographic Assessment of Improvements From Baseline Score

    Time frame: Month 3 and Month 6

    Improvement Distribution Score is based on the number of hairs per centimeters squared by macrophotographic conversion hair count. Score Range: -3 = greatly decreased to +3 = greatly increased. 0 = No change.

  12. Panel Assessment of Improvement Distribution From Screening

    Time frame: Baseline to Month 3 and Baseline to Month 6

    Improvement Distribution is based on the number of hairs per centimeters squared by macrophotographic conversion hair count.

    Score Range -3=greatly decreased to +3=greatly increased. 0=No change.

  13. The Percentage Change From Baseline in Dihydrotestosterone (DHT) at Month 3, 6, and 10

    Time frame: Month 3, Month 6 and Month 10

    Mean percent change from Baseline for DHT. DHT was measured in pg/ml. Change from baseline = Month 3, 6, and 10 values minus baseline value.

  14. The Percentage Change From Baseline in Testosterone at Month 3, 6, and 10

    Time frame: Month 3, Month 6, and Month 10

    Mean percent change from Baseline for testosterone. Testosterone was measured in ng/ml.

  15. Endocrinology Shifts in Thyroid Stimulating Hormone (TSH), Thyroxine (T4), Prostate Specific Antigen (PSA), DHT, Testosterone (T), and Luteinizing Hormone (LH) From Baseline to Month 6 and Month 10.

    Time frame: Baseline to Month 6 and Month 10

    Normal ranges: TSH, 0.25-3.50 µIU/mL; T4, 4.5-12.0 mg/dL; PSA, ≤4 ng/mL; DHT, males (m): prepuberty, <0.1, adult, 0.25-0.75; females (f): prepuberty, <0.03, premenopausal, 0.05-0.3, menopausal, <0.03 ng/mL; T, m: 2.36-9.96; f: 0.08-0.86 ng/mL; LH, m: 1-8; f: follicular, 4-12; periovulatory, >20; luteal 5-20; postmenopausal, >10 IU/L.

  16. Laboratory Values: Electrolytes Assessed at Baseline and 6 Months.

    Time frame: Baseline and Month 6

    Sodium, Potassium (mEq/L), and Bicarbonate

  17. Laboratory Values: Hematology Assessed at Baseline and 6 Months.

    Time frame: Baseline and Month 6

    Comparing Lab values and differences from Baseline to month 6

  18. Laboratory Values: Liver Enzymes Assessed at Baseline and 6 Months.

    Time frame: Baseline and Month 6

    sGOT (AST)- serum Glutamic-Oxaloacetic Transaminase, sGPT (ALT) - serum Glutamic-Pyruvic Transaminase, Alkaline Phosphatase, Bilirubin(mg/dL) and Albumin(g/dL)

  19. Laboratory Values: Other Chemistry Assessed at Baseline and 6 Months.

    Time frame: Baseline and Month 6

    Glucose, Creatinine, Ferritine (ug/L) and Zinc (Hmol/L)

  20. Sexual Function Inventory - Screening - Sex Drive, Erection, and Ejaculation

    Time frame: Screening

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem?

  21. Sexual Function Inventory - Baseline - Sex Drive, Erection, and Ejaculation

    Time frame: Baseline

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem?

  22. Sexual Function Inventory - Month 3 - Sex Drive, Erection, and Ejaculation

    Time frame: Month 3

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem?

  23. Sexual Function Inventory - Month 6 - Sex Drive, Erection, and Ejaculation

    Time frame: Month 6

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem?

  24. Sexual Function Inventory - Month 10 - Sex Drive, Erection, and Ejaculation

    Time frame: Month 10

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem?

  25. Sexual Function Inventory: Shifts From Baseline to Month 6 in Sex Drive

    Time frame: Baseline to Month 6

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem? For example, "No Problem shift to No Problem" indicates that the participant experienced no problem at baseline and no problem at Month 6, respectively.

  26. Sexual Function Inventory: Shifts From Baseline to Month 6 - Erection

    Time frame: Baseline to Month 6

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem? For example, "No Problem shift to No Problem" indicates that the participant experienced no problem at baseline and no problem at Month 6, respectively.

  27. Sexual Function Inventory: Shifts From Baseline to Month 6 - Ejaculation

    Time frame: Baseline to Month 6

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem? For example, "No Problem shift to No Problem" indicates that the participant experienced no problem at baseline and no problem at Month 6, respectively.

  28. Sexual Function Inventory: Shifts From Baseline to Month 10 in Sex Drive

    Time frame: Baseline to Month 10

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem? For example, "No Problem shift to No Problem" indicates that the participant experienced no problem at baseline and no problem at Month 6, respectively.

  29. Sexual Function Inventory: Shifts From Baseline to Month 10 - Erection

    Time frame: Baseline to Month 10

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem? For example, "No Problem shift to No Problem" indicates that the participant experienced no problem at baseline and no problem at Month 6, respectively.

  30. Sexual Function Inventory: Shifts From Baseline to Month 10 - Ejaculation

    Time frame: Baseline to Month 10

    In the past 7 days, to what extent have you considered: a lack of sex drive to be a problem?, your ability to get and keep erections to be a problem? your ejaculation to be a problem? For example, "No Problem shift to No Problem" indicates that the participant experienced no problem at baseline and no problem at Month 6, respectively.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

An Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Dutasteride 0.5mg Once Daily for 6 Months in the Treatment of Male Subjects With Androgenetic Alopecia (Norwood-Hamilton Classification Type IIIv, IV and V)

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Feb 28, 2007
Registry last updated
Aug 16, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.